Journal Article
. 2019 Oct;33(6).
doi: 10.21873/invivo.11714.

Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer

Jeeyeon Lee 1 Won Hwa Kim 2 Jin Hyang Jung 1 Wan Wook Kim 1 Chan Sub Park 1 Ryu Kyung Lee 1 Jee Young Park 3 Yee Soo Chae 4 Soo Jung Lee 4 Hye Jung Kim 2 Ji-Young Park 5 Ho Yong Park 6 
  • PMID: 31662548
  •     28 References


Background/Aim: Multigene profiling assays provide strong evidence for predicting the prognosis of breast cancer. In this study, we aimed to evaluate the clinical validation of the BCT score with various prognostic factors.

Materials And Methods: A total of 133 cases of hormone receptor-positive, cT1N0 breast cancers were analyzed. Risk stratification using the BCT score (Low, n=105; High, n=28) was analyzed with Ki67 index, p53 mutation, Immunohistochemistry 4 (IHC4) score, Nottingham Prognostic Index (NPI) and online PREDICT.

Results: Ki67 index and NPI showed strong correlations with risk stratification based on BCT scores. Although the IHC4 score and online PREDICT were not associated with BCT score, there was a significant tendency of association with the online PREDICT results as the time of overall survival was increasing.

Conclusion: Risk classification based on BCT scores might have a clinical significance as a prognostic marker in hormone receptor-positive, HER2-negative, early breast cancer.

Keywords: BCT score; Breast; carcinoma; prognosis.

The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis.
P Yang, C W Du, +2 authors, G J Zhang.
Sci Rep, 2013 Jul 23; 3. PMID: 23873310    Free PMC article.
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.
Gyungyub Gong, Mi Jeong Kwon, +15 authors, Young Kee Shin.
Sci Rep, 2017 Mar 30; 7. PMID: 28350001    Free PMC article.
Validity of the online PREDICT tool in older patients with breast cancer: a population-based study.
N A de Glas, E Bastiaannet, +6 authors, J E A Portielje.
Br J Cancer, 2016 Jan 20; 114(4). PMID: 26783995    Free PMC article.
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results.
J Jacquemier, J P Molès, +5 authors, C Theillet.
Br J Cancer, 1994 May 01; 69(5). PMID: 7514027    Free PMC article.
P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
Yunbao Pan, Yufen Yuan, Guoshi Liu, Yongchang Wei.
PLoS One, 2017 Feb 25; 12(2). PMID: 28235003    Free PMC article.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Personalized medicine in breast cancer: a systematic review.
Sang-Hoon Cho, Jongsu Jeon, Seung Il Kim.
J Breast Cancer, 2012 Oct 24; 15(3). PMID: 23091538    Free PMC article.
Significance of immunohistochemistry in breast cancer.
Dana Carmen Zaha.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114853    Free PMC article.
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, +8 authors, Young Kee Shin.
PLoS One, 2018 Nov 22; 13(11). PMID: 30462685    Free PMC article.
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.
P D Pharoah, N E Day, C Caldas.
Br J Cancer, 1999 Sep 02; 80(12). PMID: 10471047    Free PMC article.
Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.
Andrew R Green, D Soria, +9 authors, I O Ellis.
Breast Cancer Res Treat, 2016 Apr 27; 157(1). PMID: 27116185    Free PMC article.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
Ki-67 is a prognostic marker for hormone receptor positive tumors.
M E Pérez-López, J García-Gómez, +3 authors, T García-Caballero.
Clin Transl Oncol, 2016 Jan 09; 18(10). PMID: 26742937    Free PMC article.
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
E de Azambuja, F Cardoso, +7 authors, M Paesmans.
Br J Cancer, 2007 Apr 25; 96(10). PMID: 17453008    Free PMC article.
Highly Cited.
Risk Stratification and Intrinsic Subtype Classification of Breast Cancer: a Multi-Parameter Test to Rule Them All?
Rachael Natrajan, Britta Weigelt.
J Natl Cancer Inst, 2016 May 01; 108(9). PMID: 27130931
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer.
Jae-Myung Kim, Jai Min Ryu, +6 authors, Jeong Eon Lee.
J Breast Cancer, 2018 Jul 03; 21(2). PMID: 29963119    Free PMC article.
p53 expression in breast cancer related to prognostic factors.
D Ciesielski, A Dziewulska-Bokiniec, +3 authors, J Wojtacki.
Neoplasma, 1995 Jan 01; 42(5). PMID: 8552201
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Carmen Criscitiello, Davide Disalvatore, +12 authors, Giuseppe Curigliano.
Breast, 2013 Dec 10; 23(1). PMID: 24314620
Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
L Temmim, H Baker, F Sinowatz.
Anticancer Res, 2001 Apr 13; 21(1B). PMID: 11299837
MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.
Anna Sapino, Paul Roepman, +15 authors, Charles E Cox.
J Mol Diagn, 2014 Jan 01; 16(2). PMID: 24378251
Clinical utility of multigene profiling assays in early-stage breast cancer.
M C Chang, L H Souter, +6 authors, Molecular Oncology Advisory Committee.
Curr Oncol, 2017 Nov 02; 24(5). PMID: 29089811    Free PMC article.
The 70-gene prognostic signature for korean breast cancer patients.
Kuk Young Na, Ku Sang Kim, +7 authors, Yong Sik Jung.
J Breast Cancer, 2011 Aug 19; 14(1). PMID: 21847392    Free PMC article.
Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm.
Jessica A Rayhanabad, L Andrew Difronzo, Phillip I Haigh, Lina Romero.
Am Surg, 2008 Oct 24; 74(10). PMID: 18942607
Interlaboratory variability of Ki67 staining in breast cancer.
Cornelia M Focke, Horst Bürger, +5 authors, German Breast Screening Pathology Initiative.
Eur J Cancer, 2017 Aug 23; 84. PMID: 28829990
A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method.
Min Hye Jang, Hyun Jung Kim, +2 authors, So Yeon Park.
PLoS One, 2017 Feb 12; 12(2). PMID: 28187177    Free PMC article.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.